Kura Oncology announced positive topline results from a phase II trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck. The phase II trial achieved its primary endpoint prior to the completion of enrollment.
LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.
